Semaglutide ' A New Pathway ' to CVD Risk Reduction: SELECT Semaglutide ' A New Pathway ' to CVD Risk Reduction: SELECT
The weight loss drug showed a consistent reduction in major cardiovascular events over a 3-year follow up in patients with a history of heart disease who were overweight or obese.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
More News: Cardiology | Cardiovascular | Eating Disorders & Weight Management | Heart | Heart Disease | Obesity | Weight Loss